Nadoksolol
| |
| Nazivi | |
|---|---|
| IUPAC naziv
N′,3-Dihidroksi-4-naftalen-1-iloksibutanimidamid
| |
| Identifikacija | |
| |
3D model (Jmol)
|
|
| ChemSpider | |
| EC broj | 252-825-2 |
| MeSH | C006154 |
| UNII | |
| |
| Svojstva | |
| C14H16N2O3 | |
| Molarna masa | 260,29 g·mol−1 |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
| Reference infokutije | |
Nadoksolol je antiaritmički agens (i.e., lek za lečenje nepravilnog rada srca),[3] hemijski srodan po strukturi sa lekovima koji blokiraju beta-adrenergičke receptore kao što je propranolol.[4]
It does not appear to be marketed anywhere in the world.
Reference
[уреди | уреди извор]- ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
- ^ Warembourg, H; Ducloux, G (1976). „Clinical study of a new anti-arrhythmia agent: nadoxolol”. Lille Med. 21 (4): 386—8. PMID 957857.
- ^ Kapoor, M; Anand, N; Koul, S; Chimni, SS; Manhas, KS; Raina, C; Parshad, R; Taneja, SC; Qazi, GN (2003). „Kinetic resolution of 1-chloro-3-(1-naphthyloxy)-2-propanol, an intermediate in the synthesis of beta-adrenergic receptor blockers”. Bioorganic Chemistry. 31 (3): 259—69. PMID 12818235. doi:10.1016/s0045-2068(03)00050-6.